Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
Objective This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA).Methods In ASTRAEA, patients with active PsA...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-06-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/5/1/e000934.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469691523760128 |
|---|---|
| author | Philip J Mease Iain B McInnes Gianfranco Ferraccioli Maria-Antonietta D'Agostino Manuela Le Bars Subhashis Banerjee Harris A Ahmad Yedid Elbez |
| author_facet | Philip J Mease Iain B McInnes Gianfranco Ferraccioli Maria-Antonietta D'Agostino Manuela Le Bars Subhashis Banerjee Harris A Ahmad Yedid Elbez |
| author_sort | Philip J Mease |
| collection | DOAJ |
| description | Objective This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA).Methods In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) ≤3.6 and <2.6, Health Assessment Questionnaire-Disability Index reduction from baseline ≥0.35 and radiographic non-progression (defined as change from baseline ≤0 in PsA-modified total Sharp/van der Heijde score). Responses were stratified by baseline BMI (underweight/normal, <25 kg/m2; overweight, 25–30 kg/m2; obese, >30 kg/m2) and compared in univariate and multivariate models.Results Of 212/213 and 210/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight/normal subgroup. In the placebo group, patients in the obese versus underweight/normal subgroup were significantly less likely to achieve DAS28 (CRP) <2.6 at week 24 (OR 0.26; 95% CI 0.08 to 0.87; p=0.03).Conclusion BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA.Trial registration number NCT01860976. |
| format | Article |
| id | doaj-art-69a3fb4c228142e5a9be23c0e20a6497 |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2019-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-69a3fb4c228142e5a9be23c0e20a64972025-08-20T03:25:23ZengBMJ Publishing GroupRMD Open2056-59332019-06-015110.1136/rmdopen-2019-000934Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trialPhilip J Mease0Iain B McInnes1Gianfranco Ferraccioli2Maria-Antonietta D'Agostino3Manuela Le Bars4Subhashis Banerjee5Harris A Ahmad6Yedid Elbez74 Swedish Medical Center and University of Washington, Seattle, Washington, USA3 College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UKDivision of Rheumatology, IRCCS—Fondazione Policlinico Universitario A. Gemelli—Catholic University of the Sacred Heart, Rome, ItalyRheumatology, Université Versailles Saint-Quentin en Yvelines, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, FranceBristol-Myers Squibb, Rueil-Malmaison, FranceBristol Myers Squibb Co, Princeton, New Jersey, USABristol-Myers Squibb, Princeton, New Jersey, USAExcelya, Boulogne-Billancourt, FranceObjective This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl (ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent response to subcutaneous (SC) abatacept in patients with psoriatic arthritis (PsA).Methods In ASTRAEA, patients with active PsA were randomised (1:1) to receive blinded weekly SC abatacept 125 mg or placebo for 24 weeks. Treatment response at week 24 was assessed by the proportions of patients achieving American College of Rheumatology 20% improvement response, Disease Activity Score in 28 joints (DAS28 (C reactive protein (CRP))) ≤3.6 and <2.6, Health Assessment Questionnaire-Disability Index reduction from baseline ≥0.35 and radiographic non-progression (defined as change from baseline ≤0 in PsA-modified total Sharp/van der Heijde score). Responses were stratified by baseline BMI (underweight/normal, <25 kg/m2; overweight, 25–30 kg/m2; obese, >30 kg/m2) and compared in univariate and multivariate models.Results Of 212/213 and 210/211 patients with baseline BMI data in the abatacept and placebo groups, respectively, 15% and 19% were underweight/normal, 36% and 27% were overweight, and 49% and 54% were obese. After adjusting for baseline characteristics, there were no significant differences for any outcome measure at week 24 with abatacept in the overweight or obese versus underweight/normal subgroup. In the placebo group, patients in the obese versus underweight/normal subgroup were significantly less likely to achieve DAS28 (CRP) <2.6 at week 24 (OR 0.26; 95% CI 0.08 to 0.87; p=0.03).Conclusion BMI does not impact clinical or radiographic response to SC abatacept in patients with PsA.Trial registration number NCT01860976.https://rmdopen.bmj.com/content/5/1/e000934.full |
| spellingShingle | Philip J Mease Iain B McInnes Gianfranco Ferraccioli Maria-Antonietta D'Agostino Manuela Le Bars Subhashis Banerjee Harris A Ahmad Yedid Elbez Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial RMD Open |
| title | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
| title_full | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
| title_fullStr | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
| title_full_unstemmed | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
| title_short | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
| title_sort | body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis a post hoc analysis of a phase iii trial |
| url | https://rmdopen.bmj.com/content/5/1/e000934.full |
| work_keys_str_mv | AT philipjmease bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT iainbmcinnes bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT gianfrancoferraccioli bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT mariaantoniettadagostino bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT manuelalebars bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT subhashisbanerjee bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT harrisaahmad bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial AT yedidelbez bodymassindexandtreatmentresponsetosubcutaneousabataceptinpatientswithpsoriaticarthritisaposthocanalysisofaphaseiiitrial |